Artiva Biotherapeutics Inc

Artiva Biotherapeutics insider sales show routine RSU tax‑cover moves, not distress, but hint at short‑term supply pressure while execs stay long‑term invested.

Artiva Biotherapeutics insiders boost confidence with RSU and ESO grants, signaling strong support for its NK‑cell therapy pipeline and potential upside for investors.